Thermo Fisher Scientific, the world leader in serving science, has introduced the rapid RT-PCR Accula Flu A/Flu B Test designed to enable healthcare providers to detect and differentiate influenza A and B in about 30 minutes. The test can guide treatment at the point of care, including at a physician’s office, urgent care center or pharmacy, as well as help providers improve patient flow, reduce the need for follow up visits and shorten wait times.
“Healthcare providers across the United States have trusted the Accula SARS-CoV-2 Test* for rapid, accurate COVID-19 test results and can now rely on the Accula Flu A/Flu B Test for their point-of-care testing needs as we enter the flu season and beyond,” said Ingo Chakravarty, vice president and general manager of rapid diagnostics solutions at Thermo Fisher Scientific. “With this launch, we are well on our way to becoming a true point-of-care testing provider. We look forward to continuing to expand our menu of rapid test offerings for the Accula platform.”
The Accula Flu A/Flu B Test provides an easy-to-read visual result and delivers the accuracy of RT-PCR tests, combined with the simplicity of antigen tests. It runs on the palm-sized, portable Accula Dock, which plugs into a standard wall outlet to enable RT-PCR testing without the need for a specialized laboratory.
Thermo Fisher Scientific acquired Mesa Biotech, the company that developed and commercialized the Accula platform, in 2021. The Accula Dock and Accula Flu A/Flu B test received 510(k) clearance and Clinical Laboratory Improvements Amendments (CLIA) waived status in 2018 from the Food & Drug Administration (FDA).
Source: Company Press Release
